Leita Stark
Family · Mantachie, MSNPI 1760719447
Payments from drug & device makers
Across 364 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$881
- AbbVie$664
- Pfizer$609
- Lilly USA, LLC$518
- Otsuka America Pharmaceutical, Inc.$487
- Amgen$395
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,45298%
- Education$1162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $881 |
| AbbVie | 60 | $664 |
| Pfizer | 43 | $609 |
| Lilly USA, LLC | 33 | $518 |
| Otsuka America Pharmaceutical, Inc. | 21 | $487 |
| Amgen | 27 | $395 |
| Bayer | 17 | $264 |
| Boehringer Ingelheim | 15 | $258 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $252 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $147 |
| GSK | 10 | $140 |
| Xeris Pharmaceuticals, Inc. | 6 | $127 |
| E.r. Squibb & Sons, L.L.C. | 8 | $126 |
| Daiichi Sankyo Inc. | 6 | $114 |
| AstraZeneca | 7 | $104 |
| Biohaven Pharmaceuticals, Inc. | 3 | $61 |
| Exact Sciences | 3 | $45 |
| Ardelyx, Inc. | 2 | $43 |
| Mylan Specialty L.p. | 3 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Lundbeck LLC | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $24 |
| Abbott | 1 | $20 |
| Bausch Health US, LLC | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Dexcom, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$116
How this compares
$5,568 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 24 | $40,616 |
| EliquisApixaban | 27 | $31,383 |
| VraylarCariprazine Hcl | 14 | $28,630 |
| FarxigaDapagliflozin Propanediol | 28 | $27,835 |
| KerendiaFinerenone | 24 | $24,164 |
| LinzessLinaclotide | 21 | $20,618 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $18,677 |
| MyrbetriqMirabegron | 24 | $17,841 |
| JardianceEmpagliflozin | 17 | $16,193 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $9,679 |
| Repatha SureclickEvolocumab | 14 | $7,883 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $5,229 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 125 | $2,174 |
| Gabapentin | 68 | $1,545 |
| Atorvastatin Calcium | 164 | $1,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $664 | $49,24835 claims |
| Lilly USA, LLCMounjaro | $518 | $40,61624 claims |
| PfizerEliquis | $609 | $31,38327 claims |
| AstraZenecaFarxiga | $104 | $27,83528 claims |
| BayerKerendia | $264 | $24,16424 claims |
| GSKTrelegy Ellipta | $140 | $18,67719 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $17,84124 claims |
| Boehringer IngelheimJardiance | $258 | $16,19317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.
Other family in Mantachie
- Nativel CollinsMantachie$73K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.